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Abstract
Fluorescent cyclic peptides are excellent chemical scaffolds to build optical
agents for molecular imaging. In addition to their favorable physicochemical prop-
erties, they can be modified with multiple organic fluorophores and generate use-
ful probes for biological assays targeting specific proteins, namely receptors or
enzymes. In this article, we review recent advances in the synthetic approaches
for the preparation of fluorescent cyclic peptides as well as some of their applica-
tions in biological imaging, from in vitro live-cell imaging studies to in vivo charac-
terization of preclinical models.
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1 | INTRODUCTION
Peptides have been increasingly employed as chemical scaffolds to
build molecular imaging agents. Peptide structures can form highly
specific interactions with their respective biological targets, and there-
fore meet one of the main requirements in the design of imaging pro-
bes, that is, high specificity.[1] However, linear peptides exhibit some
limitations that can hinder their application in biological studies. Their
lability to proteolytic enzymes—particularly in diseased tissue where
proteases may be abundant—has prompted the development of alter-
native chemical structures that can retain the molecular recognition
properties of the peptides while displaying enhanced chemical stabil-
ity.[2,3] Some of these alternative designs include the incorporation of
unnatural amino acids, such as functionalised or D-amino acids,[4–8]
into the peptide sequence as well as the cyclisation of linear peptides.
Cyclic peptides are ubiquitously found in natural products, from com-
plex macrocycles to small cyclodipeptides. The latter have been
described as extremely compact and stable entities, which can form
noncovalent self-assemblies to yield highly rigid biomimetic materials
for diverse biotechnological and biomedical applications.[9] In this
review, we will focus on cyclic peptides as frameworks to generate
useful fluorescent probes for biological imaging studies.
Most peptides, including cyclic peptides, do not contain chemi-
cal groups that enable their detection by conventional techniques
used in the biology labs, such as fluorimetric assays, fluorescence
microscopy, or flow cytometry.[10] As a result, organic fluorophores
have been incorporated into the peptide sequences to produce
detectable contrast between the target cells and their surrounding
microenvironment.[11] Furthermore, fluorescent cyclic peptides can
be applied to many different biological experiments, from live-cell
imaging to in vivo detection of cancer cells. Herein we review the
advances in the synthetic approaches and applications of fluores-
cent cyclic peptides in biological imaging over the last 10 years. The
review article is structured into two main sections. In the first one,
we review different cyclopeptide topologies and synthetic chemical
approaches for their labeling with small-molecule fluorophores. In
the second one, we cover different examples of biological applica-
tions for fluorescent cyclic peptides, from in vitro studies focused
on receptor expression or enzyme activity, to in vivo experiments in
preclinical cancer models.
This article is dedicated to the memory of Prof. Nick Read for his contributions to the use of fluorescent peptides in biological imaging.
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2 | CHEMICAL SYNTHESIS OF
FLUORESCENT CYCLIC PEPTIDES
2.1 | Synthetic approaches for fluorescent peptide
labeling
Natural aromatic amino acids such as tryptophan, tyrosine and phe-
nylalanine exhibit intrinsic fluorescence in the ultraviolet range (λexc:
257-280 nm, λem: 282-350 nm)
[12] and have been successfully
employed in the development of green fluorescent protein (GFP)
mutant variants or fusion tag structures for fluorescence protein label-
ing.[13,14] Nonetheless, their limited optical properties (e.g., short exci-
tation and emission wavelengths, low brightness and photostability)
have hampered their extensive use as biological dyes. Most com-
monly, the generation of fluorescent cyclic peptides for bioimaging
relies on the chemoselective incorporation of an external fluorophore
with suitable spectral properties into an appropriate position within a
bioactive peptide. Careful attention of such parameters during probe
F IGURE 1 Legend on next page.
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design is crucial to afford the desired bioimaging performance. At pre-
sent, significant advances on synthetic chemistry have given rise to a
diverse array of fluorophore options, many of them commercially
available (Figure 1A). Dyes based on fluorescein, rhodamine, cyanine,
and boron dipyrromethene (BODIPY) organic molecules are among
the most popular fluorescent labels to date aimed to decipher a pleth-
ora of functions in biological systems.[15–21] Despite currently avail-
able options, new fluorophores with longer emission wavelengths and
lower background fluorescence are in pressing need. Indeed, numer-
ous efforts have been made to progress in the development of new
near-infrared (NIR) fluorescent probes, particularly those with emis-
sion peaks appearing in the spectral range of the silent optical window
(650-900 nm),[22] due to their deep penetration capabilities which can
overcome photon attenuation in living tissue.[23] In addition to the tra-
ditionally explored squaraine and cyanine dyes, recent directions of
new NIR fluorophores have pointed out the extension of the aromatic
core of BODIPY or rhodamine scaffolds due to their excellent fluores-
cence quantum yields and photostability. Particularly, the hydrophilic-
ity of rhodamine owing to its cationic character is considered an
attractive feature for biological applications. Nonetheless, the explora-
tion of further generations of these dyes is still an attractive and
emerging topic of research.[24] The self-assembling of minimal cyclic
peptide structures has also been implemented for the preparation of
NIR nano-cluster chromophores with potential use in biological sys-
tems (Figure 1B).[25]
Over the past few decades, new approaches to improve the
signal-to-noise ratios have been described. Activatable fluorophores,
which are able to turn-on their fluorescence according to the charac-
teristics of their surrounding environment, have attracted the atten-
tion of different disciplines because of their improved capabilities for
imaging and wash-free features.[26–31] To achieve these fluorogenic
properties, different sensing mechanisms have been successfully
exploited, including aggregation-induced emission (AIE), photoinduced
electron transfer (PeT), fluorescence resonance energy transfer
(FRET), intramolecular charge transfer (ICT), and spirocyclisation. As
an example, Liu, Tang and coworkers reported a theranostic probe for
simultaneous drug delivery in cancer cells and in situ evaluation of its
therapeutic killing response (Figure 1C).[32] The probe was composed
of a platinum (IV) prodrug linked to a tetraphenylsilole (TPS) fluo-
rophore with AIE sensing capabilities, a caspase-3 specific peptidyl
apoptosis sensor and a cyclic peptide for targeting cancerous cells. On
this system, only after activation of caspase-3 enzymes, the TPS fluo-
rophore was cleaved from the apoptosis-sensing peptide sequence,
triggering the AIE effect of the fluorophore and, therefore, turning the
fluorescence on. Similarly, AIE-based phenomena has also been
applied on minimal cyclic peptides for the detection of phenolic
drugs.[33] Some PeT-dependent BODIPY fluorophore systems have
been found to be sensitive to the polarity environment, showing
increased fluorescence quenching in different microenvironments or
upon binding to various analytes.[34–39]
Depending on the anchoring functional groups, the incorporation
of the fluorescent moiety into the cyclic peptide is performed either
before or after the cyclisation step through different covalent linkages
such as amide,[40–42] thioamide,[43] and thioether[44] bonds, the former
being the most widely applied (Figure 1D).[45] Additionally, numerous
attempts have been made to explore alternative approaches.[46] When
the coupling of the fluorophore takes place prior the cyclisation step,
the amino or carboxylic acid terminal positions of the linear peptides
are the preferred reactive points. For instance, Tamamura et al.
reported a cyclic peptide inhibitor of the epidermal growth factor
receptor (EGFR) evolved from the disulfide bond ring closure between
two Cys residues and fluorescently labeled with fluorescein at the N-
terminus through an amide bond linkage.[47] Nonetheless, most com-
monly the peptide ring closure involves both the α-amino and acid ter-
minal functional groups. Therefore, the fluorophore is generally
coupled after the cyclisation step to nucleophilic groups placed on the
side chains of the peptide sequence, such as Cys (thiol), Ser (hydroxy),
and Lys (amino), being the latter the most popular choice among
F IGURE 1 Common fluorophores and strategies for fluorescent peptide labeling. A, Representative selection of fluorescent cores (black and
white) and reported fluorophores (colored) for the preparation of fluorescent cyclic peptides covering the blue to NIR fluorescent range. B, NIR
nano-cluster chromophores evolved from the peptide self-assembling of tryptophan-tryptophan cyclic dipeptides (cyclo-WW) and Zn(II).
Chemical Structure of cyclo-WW (top). Transmission electron microscopy image of the cyclo-WW + Zn(II) spherical nanospheres (middle) Scale
bar: 300 nm. Emission spectra of the nanospheres in DMSO in a range of different excitation wavelengths (bottom). C, Mechanism of action of
the multifunctional theranostic probe TPS-DEVD-Pt-cRGD for the in situ early evaluation of cisplatin drug effect in cancer cells by aggregation-
induce fluorescence emission (left). Photoluminescence (PL) spectra of TPS-CH2N3, apoptosis sensor TPS-DEVD and TPS-DEVD-Pt-cRGD in
DMSO/PIPES (v/v = 1/199) (right). Inset: corresponding pictures taken under irradiation of a UV lamp at 365 nm. D, Common amino acid side-
chain coupling reactions for the chemical incorporation of fluorophores (FL) into cyclic peptides. E, Application of pCAP in SPPS for the
preparation of the cell permeable c[(pCAP)FΦRRRRQ] peptide to detect intracellular tyrosine phosphatase (PTP) activity. Fixed-cell confocal
microscopy images of MCF-7 human breast cancer cells treated with the labeled peptide (5 μM, blue fluorescence) and the nuclear stain DRAQ5
(red fluorescence) with and without pre-treatment with 1 mM sodium pervanadate as a PTP inhibitor (top). Trp-BODIPY amino acids with green
and red fluorescent emission applied for the preparation of fluorescent cyclic peptides on SPPS. Representative example of c[RKKW(BODIPY)
FWG] peptide with green fluorescent emission upon selective binding with Aspergillus Fumigatus fungal cells. Time-lapse high-resolution imaging
of A. fumigatus upon incubation with a cell membrane counterstain (red) and the peptide (2 mM, green) for 0 and 10 minutes, respectively. Scale
bar, 2.5 mm. (bottom). All images in part B were reproduced with permission from reference 25, Springer Nature Limited [publisher of ref. 25], the
image in part C was reprinted (adapted) with permission from (Y. Yuan, R. T. K. Kwok, B. Z. Tang, B. Liu, J. Am. Chem. Soc. 2014, 136, 2546-2554),
copyright (2014) American Chemical Society and all images in part E were reprinted (adapted) with permission from (Z. Qian, T. Liu, Y. Y. Liu,
R. Briesewitz, A. M. Barrios, S. M. Jhiang, D. Pei. ACS Chem. Biol. 2013; 8, 423-431), copyright (2013) American Chemical Society and reference
54, Springer Nature Limited [publisher of reference 54]
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all.[48,49] If required, the fluorophore conjugation is also extended with
an additional linker spacer (e.g., PEG) to prevent steric hindrance
interference of the fluorophore with peptide target recognition or to
modulate chemical properties such as probe solubility. Lin, Yong and
coworkers reported the incorporation of a 800CW cyanine dye to a
peptide targeting tumor angiogenesis using a PEG spacer to improve
the long-term circulation of the probe.[50]
An emerging alternative strategy of fluorescence peptide label-
ing relies on the direct preparation of non-natural fluorescent
amino acid derivatives as building blocks for standard solid-phase
peptide synthesis (SPPS).[10] This method affords great flexibility as
it enables the selective incorporation of dyes anywhere in the pep-
tide sequence using conventional SPPS procedures[51] and without
the need of orthogonal side-chain protecting groups. On this basis,
Pei and et al. reported a cell permeable peptide for detecting intra-
cellular tyrosine phosphatase activities by embedding of a non-
fluorescent phosphocoumaryl aminopropionic acid (pCAP), which
behaves as a phosphotyrosine analogue, so that selective dephos-
phorylation by protein tyrosine phosphatases released the couma-
rin fluorescence (Figure 1E).[52] Recently, our group designed novel
fluorescent Trp-BODIPY amino acids with green and red fluores-
cent emission that exhibit a fluorogenic behavior upon selective
peptide target binding and also retain the lipophilic character of the
native tryptophan, avoiding the modification of polar groups (e.g.,
amines and thiols) that may me crucial for the biological properties
of the peptide (Figure 1E). These versatile amino acids have been
successfully applied for the preparation of fluorescent cyclic pep-
tides to image different processes associated with fungal infections
and cancer.[53–56]
2.2 | Different fluorescent cyclopeptide topologies
In comparison to their linear counterparts, cyclic peptides possess
reduced conformational freedom, which can result in improved biolog-
ical properties. Constrained structures exhibit more resistance to
chemical or enzymatic hydrolysis, better cell permeability and bind to
their molecular targets with higher affinity and selectivity, enhancing
their potential as therapeutics and biochemical research tools.[57,58]
The synthetic preparation of cyclic peptides (typically around 5-14-
mer) either mimicking natural structures or displaying novel arche-
types is achieved through diverse approaches including phage display
technology, split-intein circuit ligation, mRNA display, combinatorial
chemistry as well as de novo synthesis. Thanks to their oligomeric
nature based on sequential amino acid units conforming the amide
bond backbone skeleton, automated SPPS approaches can be easily
implemented. A representative example of a natural-mimicking
cyclopeptide used for bioimaging purposes is octreotide, a somato-
statin-like peptide which has been fluorescently labeled with fluores-
cein isothiocyanate for potential clinical usage in cancer diagnosis.[59]
In another example, GX1, a cyclic 9-mer peptide identified by phage
display technology, was labeled with a cyanine dye for fluorescence
imaging of tumor vasculature.[60] According to the positions involved,
peptide ring closure can be formed between the N-terminal and the
C-terminal end, between side chains to either terminus or in between
side chains through amide (homodetic) or other chemically stable
bonds (heterodetic), such as disulphide bridges or ether, lactone and
thioether linkages. Besides, other more complex cyclic topologies
have also been produced thanks to the development of new chemical
cross linker strategies in addition to traditional disulfide bond linkages
between two Cys residues. In an example, a BODIPY-based fluo-
rophore was conjugated to the C-terminal position of a stapled pep-
tide evolved from the direct linkage of phenyl and tryptophan
residues through a palladium-catalyzed CH activation reaction.[61]
Alternative approaches involve the generation of cyclopeptide
adducts whose fluorescence is encoded in the peptide sequence. An
illustrative example was shown by Perrin et al., who prepared bicyclic
fluorescent peptides via the condensation of an ortho-phthalaldehyde
unit with the amine and thiol reactive groups of a cyclic peptide pre-
cursor to yield a fluorescent isoindole staple.[62] Other examples
include the coordination of an iridium complex to the imidazole
groups of histidine side chains of an RGD-containing peptide for
simultaneous cyclisation and luminescence formation[63] and a double
“click” cyclisation reaction from two biscyclooctynylated units of a lin-
ear precursor to yield cyclopeptide adducts bearing a bisazide fluo-
rogenic dye.[64] Despite the simplicity of inherent fluorescent cyclic
peptides, they often show suboptimal characteristics (e.g., wave-
lengths, quantum yields) for widespread application in molecular
imaging.
Among all the cyclic peptide sequences described for the devel-
opment of molecular imaging agents, special mention should be
made to the Arg-Gly-Asp (RGD) tumor-homing motif for being one
of the most prominent structures (Figure 2). The RGD motif has a
long history of being used in the targeting of integrin transmem-
brane receptors, including α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8,
and αIIbβ3 subtypes. Among all these, αvβ3 integrin, with an impor-
tant role in the early phase of tumor forming and metastasis and
overexpressed in several types of cancer, is currently the most
widely studied.[65] RGD-containing cyclopeptides for αvβ3 integrin
are predominantly based on the -RGDfV-,[66] -RGDyK-,[67] and
-RGDfK-[42,68] sequences to afford improved target affinities,
although other motifs have also been explored. For instance, the
iRGD motif, whose cyclisation results from a disulfide bond
between two Cys side chains groups, shows more efficient tumor
penetration[69] and better cell internalization[70] for improved thera-
peutic performance. Chen et al. reported a NIR fluorescent iRGD-
based peptide with affinity for αvβ3 integrin receptor with higher
cellular staining for tumor-targeted imaging.[44] In another example,
a dual-cargo iRGD peptide bearing two fluorescent dyes on each
terminus was synthesized by Kim and coworkers to separately track
the endocytic internalization and delivery of different fragments in
cancer cells. In comparison to a control peptide having a non-iRGD
sequence, such probe displayed better tumor imaging contrast.[71]
More recently, efforts have been devoted to design RGD
cyclopeptides to selectively image other relatively unexplored
integrin receptors, such as αvβ8, with promising results.[72]
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The advancement on the development of new RGD probes have
also given rise to the generation of novel systems. Smith and
coworkers prepared a noncovalent probe by coupling a squaraine dye
within a tetralactam macrocycle embedding a c(RGDfK) cancer
targeting peptide.[73] This system exhibited remarkable high photo-
stability and low phototoxicity for the fluorescent NIR detection of
tumor cells in vivo. Further examples include a highly branched
nanoprobe architecture evolved from the conjugation of c(RGDfK)
peptide and a NIR cyanine dye onto polyamidoamine dendrimers for
the identification of early stage esophageal squamous cell carcinoma
and with potential theranostic applications.[74] Achilefu et al. reported
the coupling of a NIR carbocyanine fluorophore to two units of
c(RGDfK) peptide through their respective lysine side chains.[75] This
approach achieved remarkable improvement in αvβ3/αvβ5 integrin
binding affinity and tumor uptake compared to monovalent precur-
sors. Similarly, Liu et al. reported a fluorescent probe bearing two
cRGD moieties connected through different linkers to afford higher
stability and faster binding kinetics for such receptors.[76]
3 | BIOLOGICAL APPLICATIONS OF
FLUORESCENT CYCLIC PEPTIDE PROBES
As partially described in the section above, fluorescent cyclic peptides
have been described for multiple applications in biological studies,
from in vitro cell-based assays to in vivo imaging studies. Furthermore,
their molecular versatility has facilitated their use for targeting differ-
ent proteins, from cell-surface receptors to active enzymes or intracel-
lular proteins. In this section, we will review some of the reported
applications of fluorescent cyclic peptides for biological studies.
Many of the reports considering fluorescent cyclic peptides are
focused on targeting biological receptors that are over-expressed in
tumor tissues. As an example, Lu, Chen and coworkers developed
Cy5.5-LyP-1, a tumor lymphatic-specific peptide including the fluores-
cent dye Cy5.5 to visualize lymphangiogenesis in tumor-draining
lymph nodes.[77] This technology holds promise to detect high risk
lymph nodes before tumor metastasis and after micro-metastasis. Fur-
thermore, this peptide could accelerate the development of
F IGURE 2 RGD-containing fluorescent cyclic peptide structures. Representative selection of peptide sequences including RGD motif:
c(RGDyK), c(RGDfK), and c(RGDfV) peptides selective for αvβ3 integrin receptor, disulfide-based c(CRGDC) peptides named iRGD and divalent
fluorescent RGD conjugates for improved tumor-targeted imaging, and c[GLRGDLp(NMe)K] peptide for selective imaging of αvβ8 integrin
receptor. FL, fluorophore
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antilymphatic therapeutics and improve our understanding of the
interactions between cells in primary tumors and the tumor draining
lymph nodes.
Other studies with fluorescent cyclic peptides have been focused
on cell imaging by taking advantage of some differences (e.g., xenobi-
otic uptake) between diseased and healthy cells. The cyclic peptide
analogue c(WXEAAYQkFL) was coupled to a carboxyfluorescein label
through the amino group on the side chain of the D-lysine residue.[78]
This new cyclic peptide proved to be preferentially uptaken by breast
cancer cells and was used to detect them in human blood. Other con-
jugates using this peptide sequence include theranostic probes where
the peptide was linked to chemotherapeutic drugs, such as doxorubi-
cin, in order to increase their target efficacy.[79]
Fluorescent cyclic peptides can be also directed to specific com-
partments of the cell. Our group previously reported the fluorogenic
Trp-BODIPY amino acid to prepare an environmentally-sensitive ana-
logue of the antimicrobial cyclic peptide PAF26 with high affinity for
the membranes of fungal cells.[54] In this case, the use of a fluorogenic
label enabled to brightly stain the membranes of the fungal pathogen
Aspergillus fumigatus with high signal-to-noise ratios and without the
need for washing steps (Figure 1E). In another example, Trp-BODIPY
amino acid was employed for the preparation of a fluorescent cyclic
lactadherin mimic for the detection of apoptotic bodies[55] as well as a
fluorescent cyclopeptide for the quantification of drug-induced apo-
ptosis,[80] displaying strong binding in a Ca2+ independent-manner,
unlike the gold standard for apoptosis detection Annexin V.
Fluorophore-bearing oligomers of cyclic dipeptides have also been
implemented for the intracellular delivery of pDNA.[81] Other peptides
have been described to target intracellular organelles. On this basis,
the rapid uptake and subcellular localization of fluorescently-labeled
analogues of the cyclic depsipeptide kapakahine E was reported.[82]
Specific localisation within the Golgi apparatus was confirmed by
colocalization experiments with other commercially-available markers.
Nucleic acids are another example of widely targeted macromolecules
inside cells. Yavin and coworkers synthesized FITC-labeled peptide
nucleic acids with a cyclic structure and confirmed their uptake in
U87MG glioblastoma cells as well as their blocking function of miR-
155, a reported oncogenic miRNA.[83]
Cyclic fluorescent peptides have also been developed to target
liposomes. In the work reported by Dreher and coworkers, a novel
cyclic peptide including the NGR motif (cKNGRE) was conjugated to
the pH-sensitive Oregon Green dye.[84] These conjugates showed
good affinity to the CD13 marker found in cancer cells, and were fur-
ther used to favor the delivery of doxorubicin into tumors.
3.1 | Fluorescent cyclic peptides targeting cell
receptors
As described before, cyclic peptides including the RGD structure can
bind to integrin-type receptors with high affinity. Vahrmeijer et al.
designed a fluorescent cyclic peptide including a cyclic RGD motif and
label it with the NIR ZW800-1 dye for intraoperative imaging. The
NIR peptide was found to bind multiple integrin receptors and there-
fore could be used to detect different types of cancer.[85] In an
attempt to improve the cellular uptake performance, the group of
Smith described the preparation of novel fluorescent probes including
the squaraine fluorophore with deep red fluorescence emission.
Squaraine dyes were conjugated to a collection of cyclic RGD-
containing peptides with variable targeting properties in ovarian can-
cer cells and the divalent conjugate was found to exhibit the highest
cellular uptake.[86] In another example, Tang, Liu and coworkers built
up a cyclic RGD peptide with AIE characteristics and a caspase-
activatable motif so that increased fluorescence was observed in
regions with high caspase activity.[87,88]
Another important cell-surface receptor that has been targeted
with fluorescent cyclic peptides is the hepatocyte growth factor
receptor (HGFR), also called c-Met. This receptor is present on the
surface of tumor cells in several types of cancer, such as gastric carci-
noma,[89] ovarian cancer,[90] and colorectal polyps,[91] Among others.
Using a randomized platform to produce non-natural macrocyclic pep-
tides, Suga, Lee, and coworkers optimized a HGFR-binding macrocy-
clic peptide that was subsequently labeled with fluorescein. The
peptide showed high c-Met binding affinity in gastric carcinoma cells
and showed promising results for in vivo imaging.[89] Similarly, the
Cy5-labeled cyclic peptide GE137 was reported by Burggraaf et al. as
a molecular probe to detect HGFR in ovarian cancer cells (Figure 3A).
The peptide sequence included two disulphide bonds between four
cysteine residues, which were essential for high binding affinity to the
receptor. The GE137 peptide displayed specific binding to c-Met in
colorectal polyps, as well as good water solubility.[91]
Oxytocin receptors are another interesting group of proteins that
have been widely studied. Like other hormones, oxytocin has important
functions as chemical messengers and key roles in the reproductive sys-
tem. To further study these receptors, Karpenko et al. reported the con-
jugation of a stable version of oxytocin, named carbetocin, to the
environmentally-sensitive Nile Red dye using a PEG spacer and pro-
duced a turn-on fluorescent probe with improved capabilities for oxyto-
cin imaging.[92] The related vasopressin-type receptors have been also
subject of study because of their neuroendocrine effect as well as cogni-
tive and behavioral functions, among others. In this context, the group
of Manning reported the first peptide to detect the specific localisation
of V1b-type vasopressin receptors in brain. The fluorescent cyclic pep-
tide was based on the structure of vasopressin (d[Leu4, Lys8]VP)[93] and
included one molecule of AlexaFluor 647 as the fluorophore.
Recently, our group disclosed the preparation of a red fluorescent
analogue of a cyclopeptide with high affinity for keratin-1 (KRT1) cell
receptor, overexpressed in aggressive breast cancer tumors, that
enabled the simultaneous imaging of KRT1+ cancerous cells in combi-
nation with tumor-associated macrophage markers in tumor tissue
samples (Figure 3B).[56] Finally, other peptides have been reported to
target EGFR, which is central in multiple signaling pathways related to
cell proliferation and differentiation. EGFR are often over-expressed
in cancer cells and Tamamura et al. described a series of cyclic
decapeptide analogues including a bright fluorescein moiety as func-
tional inhibitors of the dimerization between the EGF monomers.[47]
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3.2 | Fluorescent cyclic peptides targeting
enzymes
Matrix metalloproteinases (MMPs) are enzymes with proteolytic activ-
ity against a broad range of extracellular matrix proteins. MMPs are
involved in the cleavage of cell surface receptors as well as in the
release of apoptotic ligands and activation of chemokines.[94] MMPs
are essential enzymes and play important roles in multiple biological
processes, such as proliferation, migration, adhesion, and differentia-
tion among others. Gelatinases are a subgroup of MMPs that have
F IGURE 3 Legend on next page.
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been described in tumor progression, angiogenesis, and metastasis.[95]
Li and coworkers described fluorescent cyclic peptides bearing the
HWGF motif and a fluorescent Cy5.5 reporter.[96] Notably, two differ-
ent cyclisation strategies were pursued, and cyclic peptides were
either formed by disulphide bonds or via intracellular amide linkages.
The two different conjugates were compared for binding to the target,
and the latter exhibited greater stability, providing an efficient probe
to image gelatinases. Similarly, Jeong et al. designed a Cy5.5-labeled
fluorescent cyclic peptide for imaging of the enzyme MMP-2, which
was detected in colonic lesions of an inflammation-induced colorectal
cancer model.[97] More recently, Xue et al. described a novel chemical
method to analyze the intracellular activity of AKT.[98] AKT plays a
crucial role in cell survival, being related to oncogenesis and tumor
maintenance. The authors employed a FRET strategy to couple a pair
of cyclic peptides targeting two different regions of the protein: (a)
the phosphorylated site of Ser474 and (b) a distal epitope of AKT
(Figure 3C). The resulting construct displayed a fluorescent signal con-
tingent upon AKT phosphorylation and was used to profile the intra-
cellular dynamics of AKT signaling.
3.3 | Fluorescent cyclic peptides targeting other
biomolecules
The complexes between fibrin and fibronectin are abundant in the
tumor microenvironment but they are rarely present in normal tissues.
This feature makes them valuable targets for tumor imaging. In this
context, Wang et al. described the cyclic peptide iCREKA for targeting
and imaging the tumor stroma.[99] FITC-labeled iCREKA peptides dis-
played binding to fibrin-fibronectin complexes and subsequent per-
meabilisation into glioma cells.
In a related context, the extra domain B of fibronectin (EDB-FN)
mediates cell adhesion and migration, and its expression is related to
multiple processes in cancer. To specifically target EDB-FN in prostate
cancer, Lu and coworkers designed a Cy5-labeled cyclic version of the
ZD2 peptide (sequence: CTVRTSADC).[100] This peptide showed good
capabilities for optical molecular imaging and potential applications
for the diagnosis and treatment of prostate cancer. Alternative
approaches for targeting proteins with NIR fluorescent peptides
include the cyclic albumin-binding domain peptide conjugated for lym-
phatic imaging[101] or the histone H1-binding peptide for imaging apo-
ptosis in vivo as a response to anticancer treatments.[102]
Actin is one of the most abundant proteins in eukaryotic cells and
is widely involved in cell division and cell signaling. On this basis, ana-
logues of the natural cyclic peptides jasplakinolide and chondramide
C, which behave as actin-stabilizing structures, have been rationally
designed and optimized. These peptides have been modified with a
green fluorescent BODIPY reporter and used for imaging static actin
in fixed permeabilized as well as nonpermeabilised cells.[103] This
study rendered nontoxic cyclic peptides as nontoxic and cell-
permeable probes to selectively image static, long-lived actin filaments
against dynamic F-actin and monomeric G-actin populations in live
cells, with negligible disruption of rapid actin dynamics. More recently,
Lukinavicius and coworkers have described rhodamine derivatives of
jasplakinolide which are efflux-insensitive and enabled G- and F-actin
structures in live cells.[104]
3.4 | In vivo imaging using fluorescent cyclic
peptides
A major feature of fluorescence imaging is its capability to visualize
biological systems at multiple levels, from microscopy images with
subcellular resolution to whole-body images where probes found in
different tissues within a living organism can be monitored simulta-
neously. In vivo imaging is advantageous in that it allows examination
of a biological question in the native microenvironment and under
physiological conditions. Many probes for in vivo imaging, particularly
fluorophores emitting in the NIR region of the spectra,[105–109] have
been described.
In the last 15 years, there has been a lot of interest to modulate
the optical properties of fluorescent scaffolds[110–113] (e.g., excita-
tion/emission, water solubility, fluorescence lifetime) to generate
probes with improved characteristics for in vivo imaging. In addition
to widely used commercial fluorophores, such as cyanines or rhoda-
mines, fluorophores with additional features have been developed.
Achilefu et al. reported a pH-sensitive construct composed of a pH-
activatable cyanine dye and cyclic RGD peptide for targeting and
F IGURE 3 Examples of applications of fluorescent cyclic peptide probes. A, GE137 fluorescent peptide with selective targeting against c-Met
receptor in ovarian cancer cells. ex vivo fluorescence microscopy images of tissue sections from normal colon and adenomatous polyp biopsies
taken after GE137 administration (red fluorescence) and overlap (shown in yellow) with immunohistochemical staining for c-Met (bottom left).
Simultaneous white and fluorescent colonoscopy images from patients, showing representative lesions with increased fluorescence (a-f, bottom
right). Polyps are indicated by the white arrows. B, Fluorogenic Trp-BODIPY (red) cyclopeptide targeting Keratin 1 (KRT1) protein for imaging of
aggressive carcinomas. ex vivo tissue imaging of aggressive carcinomas displaying multicolour staining of tumor-associated macrophages with
anti-Iba1 (green), KRT1+ cells with peptide (red) and DAPI nuclear stain (blue) (right). macrophage-cancer cell interactions are identified with
white arrows. Scale bar: 10 mm. C, Förster resonance energy transfer (FRET)-based phosphorylated AKT (pAKT) detection strategy for profiling
intracellular AKT protein kinase activity based on the dual coupling of two probes: a rhodamine-cy(GSQTH) peptide targeting the K386-S398
epitope (probe 1, blue) and a cyanine5-cy(YYTYT) peptide targeting the phosphorylated site of Ser474 of AKT (probe 2, red). The resulting
construct displayed the red fluorescent signal of probe 2 only upon AKT phosphorylation. All images in part A were reproduced with permission
from ref. [91], Springer Nature Limited [publisher of ref. 91], the image in part B was reproduced with permission from ref. [56], published by The
Royal Society of Chemistry, and all images in part C were reprinted (adapted) with permission from (S. Shao, Z. Li, H. Cheng, S. Wang, N. G.
Perkins, P. Sarkar, W. Wei, M. Xue. J Am Chem Soc. 2018; 140, 13586-13 589), copyright (2018) American Chemical Society
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imaging acidic tumor lysosomes in an orthotopic breast tumor mouse
model.[114] The groups of Vahrmeijer and Frangioni reported zwitter-
ionic NIR fluorophores which were incorporated into cRGD peptides
for tumor imaging (Figure 4A).[85,115] These peptides were compatible
with protocols used during surgery and showed potential for real-
time imaging of cancer cells with low background fluorescent signals.
In another approach, fluorescent magnetic nanoparticles were conju-
gated to the cyclic RGDyE peptide for hybrid magnetic resonance
and optical in vivo imaging of human breast tumors, showing no acute
toxicity.[116]
In addition to the use of sophisticated fluorophores, another
strategy to improve the in vivo imaging performance of fluorescent
cyclic peptides relies on the modification of the conjugated peptides,
such as structures with dual targeting capabilities, minimal in vivo tox-
icity and enhanced biodistribution. For instance, Lou, Xia and
coworkers designed a fluorescent construct composed of cNGR
and cRGD peptides for dual targeting of CD13 aminopeptidase and
integrin receptors, respectively.[117] In another example, Boturyn et al.
designed a fluorescent probe containing the sequences cRGD and
ATWLPPR, a peptide that behaves as a specific ligand for the
F IGURE 4 Examples of in vivo imaging applications with fluorescent cyclic peptide probes. A, Near-infrared fluorescent c(RGDyK)-based
probes I to III for tumor imaging. Probe I displaying a zwitterionic structure maintains the net charge of the original c(RGDyK) molecule at
physiological pH, avoiding disruption of local protein folding, nonspecific binding and lowering the background fluorescence. Real-time
intraoperative liver (left) and lung (right) tumor detection using NIR-fluorescent probes I to III (10 nmol each) which were injected intravenously
into each mouse 4 hours before imaging. Shown are representative (n = 5 mice per group) NIR fluorescence images and a pseudocoloured merge
with color images. Open arrows indicate tumors. B, Activatable NIR-AZA fluorescent probes sensitive to intracellular acidic environments bearing
c(RGDfK) (I) or c(CRGDKGPDC) (II) cyclopeptides. (right). In vivo fluorescence imaging of probes I (13.2 nmol, upper panel) and II (10.5 nmol, lower
panel) in MDA-MB 231 human breast tumor models at different time points (left). First image of each panel shows selected tumor region of
interest (ROI) (solid circle) and three background ROIs (dashed circles). Fluorescence remained silent within the vasculature until 60 minutes
post injection, when probes began to accumulate at the tumor region. Color scale bar shows epifluorescence quantified in radiant efficiency units
[(p/sec/cm2/sr)/(μW/cm2)], min = 2108, max = 6108. FL, fluorophore. All images in part A were reproduced with permission from ref. [115],
Springer Nature Limited [publisher of ref. 115] and all images in part B were reproduced with permission from ref. [123], published by The Royal
Society of Chemistry
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neuropilin-1 protein receptor which is over-expressed in the extracel-
lular plasma membrane of tumor cells.[118] Notably, the authored com-
pared the biological effects of injecting the dual fluorescent construct
as well as the separate injection of the two peptide sequences and
found a faster and more specific accumulation in tumors of the pep-
tide conjugate, which was attributed to the stabilization of NRP1 at
the cell membrane surface. Larger constructs have been also devel-
oped, such as poly(amidoamine) dendrimers, which were modified by
incorporation of the NIR dye cypate and the iRGD peptide and used
to visualize accumulation in tumors as a potential strategy to test
delivery of anticancer drugs using dendrimers.[70]
Although the most common cyclic peptides for in vivo imaging of
tumors are based on the RGD motif due to its high binding affinity for
integrin receptors, some other cyclic peptides have shown interesting
applications. For example, Ge and coworkers reported novel cyclic
peptides bearing the RKD motif as proapoptotic ligands[119] of the
glucose-regulated protein 78 kDa (GRP78) which is over-expressed
on the cell surface of several types of cancer.[120] Similarly, and con-
sidering the high levels of endothelial growth factor receptors (EGFR)
in colorectal cancer cells, Jois et al. reported a highly stable cyclic
derivative based on the EGFR-specific peptide ligand LARLLT.[121] In
another example, a cyclic peptide including the RPMC motif and a
fluorescein reporter was described to specifically detect colon cancer
cells by targeting integrin-type receptors.[122] This peptide was
applied for real-time endoscopic tumor detection in an orthotopic
colon mouse model, even when tumors were submucosal and with
prolonged fluorescence signals after systemic injection.
Finally, one of the main translational applications of in vivo fluo-
rescence imaging is its potential use for intraoperative imaging given
the emerging interest in fluorescence-guided surgery to improve the
identification of tumor margins and optimize the outcomes of tumor
resection. In this context, O'Shea et al. recently reported a chemical
approach to enhance the signal-to-noise ratios of fluorescent cyclic
peptides by conjugating them to NIR activatable fluorophores that
preferentially emit in acidic microenvironments (Figure 4B).[123] The
authors prepared activatable constructs containing the acid-sensitive
NIR-AZA fluorophore and iRGD or cRGD peptides. The peptides were
tested in vivo in mouse models with subcutaneous tumors and showed
higher signal-to-noise ratios to the cyclic peptides that were conju-
gated to always-on NIR fluorophores.
4 | CONCLUSIONS
The notable physicochemical and biological properties of cyclic pep-
tides make them interesting scaffolds for the preparation of molecular
imaging agents. Multiple approaches for the synthesis, characteriza-
tion and validation of fluorescent cyclic peptides in biological systems
have been reported and reviewed in this article. These strategies
include the optimization of peptide constructs with unique biochemi-
cal features (e.g., improved permeability and proteolytic stability, sta-
pled peptides, high binding affinity to specific receptors or enzymes)
as well as the introduction of fluorescent labels with suitable optical
properties (e.g., from fluorogenic amino acids that turn-on upon target
recognition to bespoke NIR dyes). With a rapidly growing molecular
toolbox and well-established synthetic methodologies in place, the
applications for fluorescent cyclic peptides in biological studies will
steadily increase over the coming years. Their proven compatibility
with a broad range of imaging modalities (i.e., high-throughput
screens, multiphoton microscopy, and intravital imaging) will enable
their use in drug discovery programs for cell reprogramming[124,125] as
well as in mechanistic studies to characterize cells in tissue microenvi-
ronments[126] and in clinical applications,[127] where novel and highly
specific probes are required. We anticipate that fluorescent cyclic
peptides will also facilitate the construction of dual probes with multi-
modal character, that is, compatible with different imaging modalities
and also theranostic probes able to deliver imaging reporters as well
as therapeutic loads. Their integration into current strategies for the
preparation of activatable fluorescent prodrugs[106,128] or smart
molecular imaging agents[129] will likely produce the next generation
of smart probes able to address complex biological questions and
to assist in the development of new therapies for personalized
medicine.
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